GSK241206P50000
- 0.00
- 0.000.00%
GlaxoSmithKline Newsroom
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
India Drug Delivery Devices Market 2024, With Profiles of Pfizer, Novartis, GlaxoSmithKline, India Medtronic, Cardinal Health, B. Braun Medical, Sun Pharmaceutical, 3M, Cipla & Bayer Zydus Pharma
GSK, Relation Therapeutics Partner to Advance Osteoarthritis, Fibrotic Disease Treatments
Glaxosmithkline (GSK.US) drugs reduce the risk of death by 42% in multiple myeloma studies.
Glaxosmithkline (GSK.US) reported that a study shows its drug belantamab mafodotin can reduce the risk of death for patients with multiple myeloma at first relapse or post-relapse by 42%.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Sector Update: Health Care
GSK's DREAMM-7 Trial Shows Sustained Overall Survival Benefit For Belantamab Mafodotin Combination Versus Daratumumab Combination; Benefit Seen Early And Maintained Through Follow-up, Reducing The Risk Of Death By 42% In Multiple Myeloma At Or After...
GSK: Data Compares With Competitor Drug Johnson & Johnson's Darzalex
GSK: Data Supports Potential for Blenrep Combinations to Become Standard of Care
GSK: Data Is For Patients With Multiple Myeloma at or After First Relapse
GSK: Blenrep Is Treatment for Relapsed/Refractory Multiple Myeloma
GSK: Data Projects Patients on Blenrep Combination To Survive Nearly Three Years Longer Compared to Standard of Care
GSK: Blenrep Combination Late-Stage Trial Reduced Risk of Death by 42% in Patients With Multiple Myeloma at or After First Relapse
GSK Gets Positive Results in Blood-Cancer Drug Trial
GSK's Blenrep Combination Therapy for Multiple Myeloma Gets Priority Review in China
Oracle, Vertiv And A Health Care Stock On CNBC's 'Final Trades'
Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)
GSK's Lung Disease Treatment Application Accepted for Review in US
Blenrep (Belantamab Mafodotin) Combination Accepted for Priority Review in China in Relapsed/refractory Multiple Myeloma
Blenrep Shows Significant Overall Survival Benefit, Reducing the Risk of Death by 42% in Multiple Myeloma at or After First Relapse